Sign in
Taking people in United KingdomNo phase

Comparing health and daily needs of people with lung infection and bronchiectasis

Studies health, symptoms and care needs in adults with nontuberculous mycobacteria lung disease.

Key facts

Who runs it
University College, London
Where
London, United KingdomSee the site
Trial code
Registry title
Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)
Status
Recruiting
People taking part
80 people, planned
Started
14 Aug 2025
Planned end
1 Jun 2026
Type of study
Observational, 2 groups
Record updated
14 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with NTM lung disease who have not had antibiotics for it, and adults with bronchiectasis and no NTM infection.

Age
18 years or older, able to give informed consent.
Sex
All sexes can join.
Disease stage
Two groups: confirmed NTM pulmonary disease (British Thoracic Society criteria, with positive NTM cultures or biopsy), or bronchiectasis confirmed in medical records.
Earlier treatment
NTM group: no antibiotic treatment for NTM for at least two weeks before the study, and none before or now for NTM lung disease.
Biomarker or test result
NTM group: positive NTM culture (sputum, bronchial wash or lavage) or lung biopsy with typical changes. Bronchiectasis group: no past positive NTM culture, and a negative NTM result in the past 12 months or no earlier than 2024.

Main reasons for not taking part

  • Under 18 years, or unable to give informed consent
  • NTM group: diagnosis not confirmed, NTM reinfection, or antibiotic treatment for NTM already started
  • Bronchiectasis group: NTM lung infection now or in the past
  • Bronchiectasis group: another chronic lung disease is the main condition rather than bronchiectasis
  • Bronchiectasis group: NTM-negative results only from before 2024

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Age: 18 years or older, able to provide informed consent; NTM-PD Group:
  • Participants will be adults diagnosed with confirmed NTM-PD based on the British Thoracic Society (BTS) guidelines
  • The participant should not be on any antimicrobial therapy (at least two weeks before participation) and should not have previously received or be currently on antimicrobial therapy for NTM-PD; BTS guidelines:
  • Clinical (both required):
  • Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution CT scan that shows multifocal bronchiectasis with multiple small nodules
  • Appropriate exclusion of other diagnoses
  • Microbiological:
  • A minimum of two positive expectorated sputum culture results of the same NTM species from samples collected on separate days within 12 months before recruitment; OR
  • Positive culture results from at least one bronchial wash or lavage. OR
  • Transbronchial or other lung biopsy with mycobacterial histopathological features (granulomatous inflammation or AFB) and positive culture for NTM or biopsy showing mycobacterial histopathological features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture-positive for NTM; Bronchiectasis Group:
  • Diagnosed with bronchiectasis, as confirmed in medical records based on clinical assessment, and radiological findings
  • Never had a history of positive culture result for NTM pulmonary infection
  • The latest NTM-negative result must be within the past 12 months from the study's start date or no earlier than 2024

Who cannot take part

  • Started antimicrobial therapy for NTM-PD; Bronchiectasis Group:
  • Diagnosed with other chronic respiratory diseases considered primary conditions, rather than bronchiectasis
  • Participants with a history of NTM pulmonary infection
  • Age: Under 18 years of age, or unable to provide informed consent; NTM-PD Group:
  • No confirmation of NTM-PD diagnosis
  • Diagnosed with a reinfection of NTM-PD
  • No diagnosis of bronchiectasis or diagnosis of bronchiectasis with NTM-PD
  • NTM-negative results obtained before 2024

Where in United Kingdom

  • Royal Free London NHS Foundation TrustLondon, United KingdomContact: Naif S Sulaiman, Study ResearcherTaking people

About the trial

What the trial wants to find out

Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such as chronic obstructive pulmonary disease (COPD), bronchiectasis, or cystic fibrosis. The number of people with NTM pulmonary disease (PD) is increasing, and its management can be complex, requiring prolonged treatment with multiple, often toxic, drugs in someone who may already be frail.

Read full original descriptionShow less

Non-drug approaches, such as airway clearance techniques, structured exercise, nutritional support and psychological care are used to help manage bronchiectasis and COPD. However, there is limited evidence about their benefit in people with NTM-PD. Also, it is not clear whether these patients' health needs are different from people with bronchiectasis alone.

The investigators want to identify the most important symptoms encountered by people with NTM-PD and patient preferences for care. The study also aims to explore whether the need for non-drug measures differs between people with and without NTM-PD who have other underlying lung disease.

The research will take place at one NHS centre and involve a single assessment of 40 people with NTM-PD not using specific antibiotics to treat their NTM and 40 people with bronchiectasis but no evidence for NTM. Following consent, and mainly using questionnaires, participants will be asked about their physical and mental health, and nutritional status. Exercise capacity, muscle strength and body muscle/fat composition will also be assessed using simple tests. The total time required will be a maximum of one hour. Recruitment to the study will last around six months.

The results will help improve understanding of specific needs of people with NTM-PD and guide clinically relevant research in this area.

The 2 groups in the trial

  • Non-Tuberculous Mycobacteria-Pulmonary Disease (NTM-PD)

    People diagnosed with NTM-PD

  • Bronchiectasis

    People diagnosed with bronchiectasis but no evidence for NTM pulmonary infection

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
An Observational Cross-sectional Study Exploring Differences in Health Between People With Non-Tuberculous Mycobacteria Pulmonary Disease and People With Bronchiectasis Without NTM Pulmonary Infection.
Plain-language title
Comparing health and daily needs of people with lung infection and bronchiectasisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 May 2026